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effect on cell-associated HIV-1 by attenuating
virion infectivity through gp120 shedding
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Background: HIV-1 infected cells can establish new infections by crossing the vaginal epithelia and subsequently
producing virus in a milieu that avoids the high microbicide concentrations of the vaginal lumen.
Findings: To address this problem, here, we report that pretreatment of HIV-infected peripheral blood
mononuclear cells (PBMCs) with a 27 amino acid CD4-mimetic, M48U1, causes dramatic and prolonged reduction
of infectious virus output, due to its induction of gp120 shedding.
Conclusions: M48U1 may, therefore, be valuable for prophylaxis of mucosal HIV-1 transmission.
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The majority of new HIV infections worldwide are
acquired through heterosexual transmission. Although
receptive transmission at the vaginal mucosa is thought
to be primarily caused by cell-free virus (CFV) [1], it
may also involve transfer of HIV-infected leucocytes (i.e.,
cell-associated virus; CAV) present in semen [2,3]. The
observation that CFV infection via the vaginal mucosa
requires a ~103-106 higher virus dose [4] than is needed
to establish infection by the intravenous route suggests
that the healthy epithelium of the female genital tract is
a robust barrier to HIV transmission. However, in con-
trast to CFV, infected seminal lymphocytes or macro-
phages are capable of migrating through intact epithelia
and delivering virus directly to the submucosa or even
the draining lymph nodes. This putative ‘Trojan Horse’
infection route (Figure 1A) is supported by various stud-
ies in mouse and macaque models [4-9].
Vaginal microbicides currently under development to
prevent heterosexual HIV transmission should, there-
fore, ideally be able to inactivate virus in these migrating* Correspondence: karien@itg.be
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reproduction in any medium, provided the orleucocytes, as well as CFV. Although most candidate
microbicides, including entry inhibitors, can inhibit CAV
in vitro [10-12], their activity in vivo depends on the in-
hibitor concentrations that can be achieved in the cer-
vical and vaginal (sub) mucosa where most of the target
cells reside. A study in rabbits and macaques measured
the levels of the candidate microbicide dapivirine
(TMC120) in the cervicovaginal tissue and found that
drug-related material was primarily detected in the
superficial cellular layers of the mucosal epithelia and
not in the submucosa or draining lymph nodes [13].
Hence, following the proposed CAV or Trojan Horse
concept (Figure 1A), infected seminal leucocytes could
subvert drug pressure in the vaginal lumen by migrating
to the submucosa or regional lymph nodes. Subse-
quently, infection may be established by virions budding
from these migrating leucocytes. However, it remains
possible that initial vaginal drug exposure exerts a sus-
tained inhibitory effect on virus production or virion in-
fectivity, even after their migration to deeper tissues.
Previous in vitro evidence provides support for such a
‘memory effect’, in that pretreatment of chronically
infected cells with the non-nucleoside reverse transcript-
ase inhibitor (NNRTI) UC781 results in the release of
attenuated virus [14]. Therefore, here we investigatedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 (See legend on next page.)
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Table 1 Overview of antiretroviral compounds
Inhibitor Target EC50 (nM)a
UC781 Reverse transcriptase 35
Dapivirine (TMC120) Reverse transcriptase 5
Tenofovir (TFV) Reverse transcriptase 4800
Saquinavir (SQV) Protease 35
Lopinavir (LPV) Protease 40
Raltegravir (RLT) Integrase 18
Maraviroc (MRV) CCR5 88
Enfuvirtide (T20) Gp41 35
C34-cholesterol (C34-chol) Gp41 7.5
Griffithsin (GRFT) Glycans on gp120 1.5
M48U1 CD4 binding site on gp120 35
Soluble CD4 (sCD4) Reverse transcriptase 116
a50% effective concentration (EC50) measured in PBMCs against HIV-1 Bal.
EC50s were calculated using linear regression analysis on data of one
experiment with 6 replicates.
(See figure on previous page.)
Figure 1 M48U1 has a memory effect on cell-associated virus. A) The Trojan Horse transmission concept was modeled in vitro using
HIV-infected PBMCs which were treated for 24 h with antiretrovirals (ARVs) from different classes at 100x EC50 concentrations. Subsequently, virus
production was quantified using a Gag p24 ELISA. To mimic escape from vaginal drug pressure, the infected cells were then incubated in
ARV-free medium for three consecutive periods of 24 h. Infectivity of newly produced virions was determined after each period by titration in
TZM-bl cells and PBMCs using equal amounts of p24. B) Production of Gag p24 by infected PBMCs during 24 h treatment with eleven ARVs: the
non-nucleoside reverse transcriptase inhibitors (NNRTIs; blue) UC781 and TMC120, the nucleotide reverse transcriptase inhibitor tenofovir (PMPA;
red), the entry inhibitors (grey) maraviroc (MVC), T-20, C34-chol, griffithsin (GRFT) and M48U1, the protease inhibitors (green) lopinavir (LPV) and
saquinavir (SQV), and the integrase inhibitor raltegravir (RAL). Values are expressed relative to untreated control cultures and represent the mean
+/− SEM of at least three independent experiments, each carried out in triplicate. C) Bal infectivity of de novo produced virus by pretreated
infected PBMCs in absence of drug during three consecutive periods of 24 h. Values are expressed relative to untreated control cultures and
represent the mean +/− SEM of at least three independent experiments, each carried out in triplicate. D) Infectivity of de novo produced
transmitted/founder viruses REJO and THRO (subtype B) and Bal by M48U1 treated infected PBMCs in absence of drug during three consecutive
periods of 24 h. Values are expressed relative to untreated control cultures. E) Infectivity of wild type (black) and M48U1-resistant (red) Bal virus
produced during a 24 h period in absence of drug by pretreated infected PBMCs. Values represent the 50% Tissue Culture Infective Dose
(TCID50)/ml as measured in one experiment carried out in triplicate.
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fect on CAV. To this end, HIV-infected peripheral blood
mononuclear cells (PBMCs) were used as a surrogate for
migrating seminal leucocytes and treated with antiretro-
virals (ARVs) from different classes. Subsequently, extra-
cellular compound and CFV were removed to mimic
escape from microbicide exposure. Next, the amount of
virus produced from these cells and its relative infectiv-
ity were assessed.
Among the test compounds was the CD4-binding site
inhibitor M48U1, which inhibits the gp120-CD4 inter-
action in the nanomolar range by targeting the highly con-
served and vulnerable Phe43-cavity in the HIV envelope
[15,16], and which showed nearly complete protection in
Cynomolgus macaques when applied as a vaginal gel [17].
Most ARVs do not inhibit virus production by infected
cells
PHA/IL-2 stimulated PBMCs were infected with 2 x 10-3
multiplicity of infection (MOI) of the CCR5-tropic
subtype B strain Bal for three days and subsequently
washed extensively to remove the inoculum (Figure 1A).
Next, cells were incubated for 24 hours with ARVs from
different classes at 100x EC50 concentrations for each
compound (Table 1). The virions produced from these
cultures were then quantified in quadruplicate by a Gag
p24 capture ELISA [18]. Interestingly, pretreatment with
most ARVs did not inhibit virus production by infected
cells as compared to the untreated control cultures
(Figure 1B). However, in the supernatant of cultures
treated with the protease inhibitors (PIs) lopinavir
and saquinavir, a significantly lower (i.e., 0.5-1 log)
Gag p24 concentration was observed, likely as a result
of unprocessed Gag precursor.
Pretreatment with M48U1 affects the infectivity of de
novo produced virions
Next, we evaluated whether these ARVs affected the in-
fectivity of the virus produced. PBMCs were infected asdescribed above and were washed extensively to remove
inhibitor and incubated in fresh medium for a new
round of viral replication. After 24 h, supernatant was
harvested, and then assessed for its ability to infect
TZM-bl cells using identical viral inocula (based on
equal amounts of Gag p24). The obtained viral titers
were expressed as a percentage, relative to the untreated
control cultures (Figure 1C). Surprisingly, virions pro-
duced by PBMCs pre-treated with M48U1, were almost
completely defective (relative titer of <1%). A smaller
loss in titer was observed after treatment with the PIs
saquinavir (relative titer of 47%) and lopinavir (relative
titer of 14%), and the carbohydrate binding protein grif-
fithsin (relative titer of 31%). The same samples were
assayed in a multi-cycle infectivity assay with PBMCs,
with similar results (Figure 1C). Overall, these observa-
tions suggest a continued inhibition by some ARVs on
de novo produced virions, even after their removal. To
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Figure 2 (See legend on next page.)
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(See figure on previous page.)
Figure 2 M48U1 induces gp120 shedding. A) “Trimer VLPs” (E168K+N189A mutant) expressing trimeric Env of the subtype B virus JR-FL were
treated with graded doses of M48U1 or sCD4. Shedding was then assessed using BN-PAGE-Western blot analysis of VLP Env. Below the gel, the
density of trimeric gp41 stumps (indicated by an arrow on the gel) is shown, as determined using ImageJ densitometry software (NIH, Bethesda,
USA, http://imagej.nih.gov/ij/). Second, we coated the same trimer VLPs of JR-FL B) or the subtype B transmitted/founder viruses REJO and WITO
(C) on an ELISA plate at 20x the concentration present in transfection supernatants, treated then with graded doses of M48U1 or sCD4, as
indicated and then measured ELISA binding by mAb 7B2 that reacts with a cryptic epitope of gp41 that only becomes exposed upon the loss of
gp120 from native trimers (i.e. gp120 shedding). D) Finally, virus particles were isolated with magnetic CD44 microbeads from PBMC culture
supernatant at 0 h, 24 h and 72 h after M48U1 exposure. Gp120 was then quantified in virion and virion-free fractions using a D7324-based
gp120-ELISA. Shedding was expressed as a ratio of free gp120 in the supernatant and intact Env in the virion fraction and compared to the
untreated control cultures (i.e., medium). Values are the means +/− SEM of two independent measurements. E) Env incorporation in the virion
fraction was determined by quantifying both the gp120 and p24 content in ELISA and plotting the gp120/p24 ratio.
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supernatant containing de novo virus was collected from
the same cell cultures at 48 h and 72 h and again titrated
on TZM-bl cells and PBMCs (Figure 1A and C). For all
viruses that showed a reduced titer at 24 h, a clear in-
crease in infectivity was observed over time. Whereas in
PI-treated cultures, virion infectivity was rapidly restored
to normal levels; the virions produced by griffithsin- and
M48U1-treated cultures remained respectively two and
four times less infectious than virions from the control
cultures, as late as 72 hours post-exposure (Figure 1C).
To exclude a strain-specific effect of the lab-adapted Bal
virus, the experiment was repeated for M48U1 using the
more relevant transmitted/founder (T/F) viruses REJO
and THRO (subtype B). Similar results were obtained
with both viruses, showing a severely reduced relative
titer at 24 h (3.7% and 3.1%, respectively) that restores
to normal infectivity levels over time (Figure 1D).
The memory effect of M48U1 depends on direct
interaction between M48U1 and gp120
To assess the role of M48U1:gp120 interaction in rela-
tion to the sustained reduction in infectivity, we used a
miniCD4 resistant, but CD4 receptor binding competent
mutant virus bearing the S375R mutation (BalS375R).
This mutation is located next to the CD4 binding loop
and disrupts the molecular interaction of M48U1 with
gp120 [18]. Similar to the previous experiments, PBMCs
were infected with wild type (WT), and mutant HIV-1
Bal, subsequently treated with a variety of ARVs and
washed 24 h later. As before, cultures were then left to
produce new virions in the absence of additional ARV
pressure. For most ARVs no significant differences in
WT or mutant virus production were found after ARV
treatment. However, contrasting the low infectious titer
(<1%) of WT virus after M48U1 treatment, a normal
titer (i.e., 100%) was found for the S375R mutant virus
(Figure 1E). This result clearly indicates that the gp120:
M48U1 interaction is a prerequisite for the memory ef-
fect observed with M48U1. As CFV is removed after
treatment, the most logical target for M48U1 is thefunctional envelope proteins (Env) on infected cell
surfaces.
M48U1 induces gp120 shedding
CD4 engagement can result in the spontaneous loss of
gp120, without infection, resulting in defective gp41
stumps. To investigate whether gp120 shedding could
explain the memory effect observed for M48U1, pseudo-
virion virus-like particles (VLPs) expressing trimeric Env
of the subtype B virus JR-FL were treated with graded
doses of sCD4 or M48U1. Two assays were then used to
measure gp120 shedding. In the first assay, VLPs were
treated with sCD4 or M48U1, washed, then Env was
extracted from particles and resolved by BN-PAGE/
Western blot, as described elsewhere [19]. In this assay,
gp120 shedding was indicated by a loss of intact native
Env trimer coupled with an increase in gp41 stumps that
are left behind after gp120 shedding. In a second assay,
VLPs were treated with sCD4 or M48U1, washed, then
coated on ELISA wells and assayed for binding of mAb
7B2, which reacts with the immunodominant cluster I
epitope of gp41 that is exposed on the gp41 stumps
exposed after gp120 shedding. In both of these assays,
we used JR-FL E168K+N189A trimer VLPs generated by
protease digestion to eliminate non-functional Env from
particle surfaces, as described previously [19]. By elimin-
ating any gp41 stumps present before drug treatment,
this enhances the ability to detect new gp41 stumps that
appear as a result of drug-induced shedding. In both
assays, M48U1 caused shedding: in proportion to the
concentration of M48U1 used, there was a loss in native
trimer staining coupled with an increase in gp41 stumps
in BN-PAGE (Figure 2A) and a quantitative increase in
7B2 binding by ELISA (Figure 2B). Moreover, by the
BN-PAGE assay, 50% shedding was induced at approxi-
mately 10-fold lower concentrations of M48U1 than of
sCD4. This is reflected by the lower EC50 of M48U1
(450nM) compared to sCD4 (900nM) in neutralization
assays against JR-FL on PBMCs (data not shown). Con-
sistent with the data on JR-FL, treatment of two T/F
viruses (REJO and WITO) with sCD4 and M48U1 also
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(Figure 2C). Together, these results show that M48U1
potently induces gp120 shedding.
Memory effect of M48U1 is linked to gp120 shedding
We next evaluated whether gp120 shedding underlies
the observed memory effect of M48U1. If this were the
case, treatment of HIV-infected cells with sCD4 should
also decrease the infectivity of de novo produced virions,
as seen with M48U1 in Figure 1C. Indeed, like M48U1,
we found that virus produced from infected PBMCs pre-
treated with sCD4 was fivefold less infectious (~22%)
than the control virus (data not shown). Furthermore, if
M48U1 induces gp120 shedding in the treated cell cul-
tures, this should be reflected by an increase in gp120 in
the virion-depleted supernatant and a reciprocal de-
crease in virion-associated gp120. Therefore, virus parti-
cles were separated from culture supernatants, using
magnetic anti-CD44 microbeads (μMACS™ VitalVirus
isolation kit, Miltenyi Biotec). We then used an ELISA
to quantify gp120 in both fractions. Interestingly, at the
earliest time point, gp120 was far more abundant in the
virion-depleted supernatant of M48U1 treated cultures
than of the control cultures (Figure 2D). The ratio of
virion-free and virion-bound gp120 then gradually
decreased to reach equilibrium levels 72 h post treatment,
coincident with the time-dependent recovery of virus in-
fectivity (Figure 2D). Finally, if M48U1 induces gp120
shedding from the Env spikes embedded in the cell
membrane of infected PBMCs, this would predict a
higher incorporation of functional Env molecules in
virions produced from untreated PBMCs compared
to M48U1-treated PBMCs. Using the same method
described above, we determined the gp120 and p24 con-
centration in the virion fraction 24 h, 48 h, and 72 h after
M48U1 treatment. Functional Env incorporation was cal-
culated as the ratio of gp120 vs. p24. As shown in
Figure 2E, the results suggest that virions produced from
infected PBMCs after removal of M48U1 have a signifi-
cantly lower degree of functional Env incorporation than
control virions produced by untreated PBMCs. Once
again, and coinciding with the observed time-dependent
recovery of virus infectivity, Env incorporation is gradually
restored to control levels at 48 h and 72 h.
Implications of M48U1 in preventing mucosal HIV
transmission
Several studies have shown that infected seminal leuco-
cytes can traverse intact vaginal epithelia to reach the
submucosa and even the draining lymph nodes [2,4,7].
Although this might not be the dominant route of infec-
tion in natural HIV transmission, in the context of
microbicide use, CAV might escape high drug concen-
trations in the vaginal lumen, by migration across theepithelium that lines the female genital tract. However,
whether the initial microbicide exposure can affect virus
budding from these migrating seminal leucocytes
remains unclear. Therefore, we here evaluated the effect
of various ARVs on the virus produced after treatment
and subsequent washing of infected PBMCs. Most ARVs
had no impact on virus production or virion infectivity.
However, surprisingly, infected cells exposed to the CD4
mimetic M48U1 produced largely defective viral parti-
cles during the first 24 hours after treatment. Virus in-
fectivity was gradually restored at later time points.
These results were unexpected because the candidate
microbicide M48U1 acts early in the viral lifecycle by
preventing HIV entry into host cells through competi-
tion with the CD4 receptor. As the infected PBMCs
were washed extensively to remove M48U1 and CFV
after initial drug exposure, this ‘memory’ effect was un-
likely to be due to CFV already neutralized by M48U1 or
unbound M48U1 in the supernatant.
We hypothesized that M48U1 associates with gp120
molecules expressed on the cell membrane of infected
cells prior to viral budding. If M48U1 dissociates very
slowly from its target and is retained after washing, this
could cause the production of defective virions. How-
ever, if this were the case, one would expect a similar at-
tenuation effect for the tight-binding RT inhibitors
UC781 and TMC120. Previous studies have shown that
pretreatment of infected cells with UC781 results in a
fivefold reduction in the infectivity of de novo produced
virus, which was explained by the membrane compart-
ment hypothesis [14,20]. In this hypothesis NNRTIs,
which are sequestered in the cell plasma membrane due
to their hydrophobic nature, would be incorporated into
the membrane of nascent budding virions. The tight
binding to RT would subsequently trap the NNRTI
within the virions, rendering them defective. Although
different cells (PBMCs versus H9+ cells) and a different
read-out of infectivity (Gag p24 and firefly luciferase ver-
sus syncytium formation) were used, our results revealed
only a very small memory effect for UC781 (relative titer
of 75% on TZM-bl cells). This suggests that the NNRTIs
in our assay were removed from the PBMC cultures,
making it unlikely that the hydrophilic M48U1, which
binds to the gp120 molecules in the plasma membrane,
would be retained on its target. Hence, another mechan-
ism must explain the sustained M48U1 activity.
More than twenty years ago, soluble CD4 was shown to
disrupt the non-covalent association of the gp120 and
gp41 envelope glycoproteins when used at high concentra-
tions, rendering virions noninfectious [21,22]. Recently,
gp120 shedding was also observed to be induced by
membrane-proximal external region (MPER)-specific anti-
bodies 2F5 and 4E10 [23]. Although the antiviral effect of









M48U1 treated HIV-infected cell
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Figure 3 Proposed model explaining the memory effect of M48U1 through gp120 shedding. M48U1 induces shedding of gp120 from HIV
envelope proteins embedded in the membrane of infected cells prior to budding. This results in the production of defective virions in absence of
drug during the first 24 h post treatment. Continuous recruitment of new envelope proteins from the endoplasmic reticulum to the cell
membrane explains why infectivity is restored over-time.
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hence explain the prolonged inhibitory effect. If this is
true, then the continuous recruitment of freshly synthe-
sized HIV envelope proteins from the endoplasmic
reticulum to the cell membrane would explain why infect-
ivity is restored over-time (see model in Figure 3). Here,
we provided 4 separate pieces of evidence to support this
hypothesis. First, by BN-PAGE, we saw that treatment of
VLPs with M48U1 led to an increase in gp41 stumps
coupled with a decrease in native Env trimer (Figure 2A).
Second, M48U1-induced exposure of the cryptic 7B2 epi-
tope on gp41 stumps on VLP surfaces is also consistent
with gp120 shedding (Figure 2B). Third, the larger propor-
tion of gp120 detected in the virus-depleted supernatant
of M48U1 treated cultures is again consistent with gp120
shedding (Figure 2C). Finally, we showed that the recovery
of virus infectivity coincides with an increased incorpor-
ation of functional Env molecules in the budding viruses
(Figure 2E). Together, these observations strongly suggest
that M48U1 induces gp120 shedding at the cell mem-
brane, resulting in defective nascent virions.
From a microbicide perspective, entry inhibitors with a
memory inhibitory effect on CAV are desirable. If
infected seminal leucocytes can escape microbicide in
the vagina by crossing the mucosal barrier, they could
establish a founder population of infected target cells
that then expands locally using the influx of new target
cells recruited through outside-in signaling [24]. Low tis-
sue concentrations of microbicide are of specific concernwhen entry inhibitors are used because their hydrophilic
nature might impede compound accumulation in the
(sub) mucosa. However, if the virus budding from these
migrating leucocytes is rendered defective by prior
microbicide exposure in the vagina, a window of oppor-
tunity would be provided to eliminate these invading
cells before local infection is established.
Aside from M48U1, we also observed a decline in in-
fectivity of virus budding from cells that were pre-
treated with the PIs lopinavir and saquinavir or the
gp120-glycan binder griffithsin, although these effects
were modest compared to that of M48U1. The memory
inhibitory effect of the PIs most likely results from im-
mature virus particles that are still budding off in the
first hours after PI removal. This is supported by the
rapid restoration of virion infectivity at later time points.
Interestingly, virions from the griffithsin-treated cultures
did not completely regain their infectivity 72 h after re-
moval of the ARV. Although the observed memory in-
hibitory effect of griffithsin remains the subject of
ongoing research, it is not due to gp120 shedding (data
not shown), indicating that, even after extensive wash-
ing, at least some griffithsin is retained within the trea-
ted cell culture thereby confirming recent work of
Kouokam et al. [25].
Although current clinical trials are mainly testing re-
verse transcriptase inhibitors as microbicides, there is in-
creasing interest in combining different ARV classes into
combination microbicides to increase efficacy and to
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being a miniproteïn, the entry inhibitor M48U1 is easy
to produce, is poorly immunogenic and does not induce
anti-CD4 antibodies in vivo [26]. Together with its small
size (27 amino acids), stable conformation in denaturing
conditions (i.e., acidic pH and high temperatures) and
relative resistance towards proteases [15], M48U1 thus
has a favorable profile as potential microbicide. This was
confirmed in a recent trial with a M48U1-loaded gel
showing almost complete protection (5 out of 6 animals)
after vaginal challenge in macaques [17]. The relative
ease at which HIV escapes inhibition by antibodies or
small molecules that target the entry process, including
M48U1 argues for its use in a combination microbi-
cide [18].
In conclusion, in this study we report for the first time
that a highly potent CD4 mimetic HIV entry inhibitor,
M48U1, induces gp120 shedding at high compound con-
centrations resulting in the production of defective nascent
virions from infected primary cells up to 72 h after their
exposure to the drug. This memory effect adds to the
already interesting properties of M48U1 as a potential can-
didate for development into a combination microbicide.
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